VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or “the Company”), a biotech company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the addition of Dr. Paul Edison, Dr. Kabir Moody, and Dr. Otto Yang to the Company’s Board of Scientific Advisors. . Additionally, Dr. Guy Lalizzari has agreed to serve as the company’s external scientific advisor.
Dr. Paul Edison Senior Clinical Lecturer in Neuroscience in the Department of Brain Sciences at Imperial College London and Professor Emeritus at Cardiff University. He is also the editor-in-chief of the magazine brain connection. After his clinical training (MD), Dr. Edison earned his M.Sc. and Ph.D. From Imperial College London, he then completed his postgraduate training at the Deanship of London and was awarded a CCT by the Council of Postgraduate Medical Education and Training. He then became a Fellow of the Royal College of Physicians of Ireland and a Fellow of the Royal College of Physicians of the United Kingdom. It has been published in such prestigious magazines as brainAnnals of Neuroscience, and Neurologyand has received grants from the Medical Research Council, NIHR/HEFCE, the Alzheimer’s Society, Alzheimer’s Research UK, the Alzheimer’s Drug Discovery Foundation of America, and other funders. It cooperates closely with Novo Nordisk, GE Healthcare, Novartis, Piramal Life Sciences and Astra Zeneca. He has also received many of the best paper awards internationally and has been published in leading scientific journals. His work now focuses on neuroinflammation and the interaction between inflammation and immunity in neurodegenerative diseases and neuroinflammation, and linking them to genetic information. It also evaluates ways to modulate inflammation and amyloid in Alzheimer’s disease, and the effect of cardiovascular factors on the development of neurodegenerative diseases by clinical and preclinical studies.
Dr.. big mody He is the medical director of IMV, Inc. He is a board-certified medical oncologist. He has a wealth of oncology and immuno-oncology experience and knowledge accumulated while at Mayo Clinic as an academic oncologist focusing on gastrointestinal tumors, particularly liver and pancreatic cancers. Dr. Moody received his medical degree from St. George’s University School of Medicine, completed his residency at St. Luke’s Roosevelt Hospital in New York City, and a fellowship at Dartmouth Hitchcock Medical Center in New Hampshire. He is the co-author of numerous papers and book chapters, including several studies on the biology and novel treatment strategies of malignant liver and pancreatic tumors, and has been actively involved in leading both clinical and laboratory research on liver and pancreatic cancers.
Dr. Otto Yang Professor of Medicine, Infectious Diseases, Microbiology, Immunology, and Molecular Genetics at UCLA with a background in Clinical Infectious Diseases. His lab specializes in T-cell immunity to HIV infection, relevant to the development of immunotherapies and vaccines for HIV and other potential diseases, including cancer and other viral infections. He received his MD from Brown University, with post residency training at NYU Bellevue Hospital and subspecialty/postdoctoral training at Harvard Massachusetts General Hospital. He then pursued a fellowship at Massachusetts General Hospital, where he developed a research program studying the role of CD8+ T lymphocytes (CTLs, which are killer T cells that can destroy virus-infected or malignant cells) in the pathogenesis of HIV-1. A more recent research interest has been the role of CTL in the development of rejection in transplant patients. Dr. Yang began working with the new Compound Tissue Transplant Program at UCLA, which will perform hand and face transplants, and study the role of this immune arm in causing tissue rejection. Dr. Yang is a frequent lecturer, has received numerous research grants and funding for his work and has published over 180 peer-reviewed articles, and holds several patents in the field of HIV and immunology.
Dr.. Jacob (Jay) Lazari He agreed to act as an external scientific advisor to CytoDyn without compensation. Dr. Lallizzari has been CEO and Medical Director of Quest Clinical Research since 1997. He received his MD from the University of Pennsylvania and his MSc from the University of Virginia. He also received a BA from the University of Rochester. Board certified by the American Board of Internal Medicine. He briefly served as Chief Medical Officer of CytoDyn during 2020, as well as Chief Medical Officer of Virion Therapeutics. Dr. Lalezari served as Principal Investigator on Phase I, II, and III clinical studies of novel treatments for viral diseases such as HIV/AIDS, CMV, HPV, HSV, hepatitis B and C, influenza, RSV, and COVID-19, including the company’s clinical trials. . He has published widely and is a highly respected international speaker and patient advocate.
CytoDyn is a clinical-stage biotechnology company focused on developing and marketing leronlimab, a humanized monoclonal IgG4 antibody (mAb) designed to bind to the CC chemokine receptor type 5 (CCR5), a protein found on the surface of certain immune system cells believed to be It plays a role in many disease processes. CytoDyn is studying leronlimab in multiple treatment areas, including infectious diseases, cancer, and autoimmune diseases.
This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and phrases that reflect optimism, satisfaction, or disappointment with current expectations, as well as words such as “believe,” “hope,” “intend,” “expect,” “expect,” “project,” “plan,” “expect” and variations thereof , or the use of the future verb, identifies forward-looking statements, but their absence does not mean that the statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could differ materially from those contained or expressed due to risks and uncertainties including: (i) regulatory determinations of the safety and efficacy of leronlimab for the treatment of diseases and conditions for which we are studying the product by the Food Administration the US Drug Administration (FDA) and various drug regulatory agencies in other countries; (ii) The company’s ability to raise additional capital to finance its operations; (3) The company’s ability to meet its debt obligations; (iv) The company’s ability to appoint a permanent CEO and retain other key employees; (5) The Company’s ability to enter into partnership or licensing arrangements with third parties; (6) the company’s ability to identify patients to enroll in its clinical trials in a timely manner; (vii) the adequate and timely development, through internal resources or external consultants, of analyzes of data resulting from the Company’s clinical trials required by the Food and Drug Administration or other regulatory agencies in connection with the Company’s pharmaceutical product approval applications; (8) The firm’s ability to obtain approval for a marketable product; (ix) designing, implementing and conducting clinical trials for the company; (x) the results of the company’s clinical trials, including the potential for unfavorable clinical trial results; (11) the market for and marketability of any Approved Product; (12) the existence or development of vaccines, drugs, or other treatments that medical professionals or patients consider to be better than the Company’s products; (13) regulatory initiatives, compliance with government regulations, and the regulatory approval process; (14) legal actions, investigations or inquiries affecting the company or its products; (15) general economic and commercial conditions; (16) changes in external, political and social conditions; (17) actions or proposals of shareholders in relation to the company, its management or its board of directors; and (18) various other matters, many of which are outside the control of the company. The Company urges investors to consider specifically the various risk factors identified in the most recent Form 10-K, as well as the risk factors and cautionary statements included in the following Form 10-Qs and Form 8-Ks filed with the Securities and Exchange Commission. Except as required by law, the Company assumes no responsibility to update any forward-looking statements to take into account events or circumstances occurring after the date of this press release.
Christina de Leon
Joe Germani / Miller Winston
Longacre Square Partners
firstname.lastname@example.org / email@example.com